Earnings Releases·Nov 12, 2026, 7:38 AM ET

Taysha Gene Therapies — Third Quarter 2026 Earnings Summary

Revenue remained $0 for the three and nine months ended September 30, 2026, while net loss widened to $39.1 million ($0.10/share) for the quarter and $128.2 million for the nine-month period compared to $32.7 million and $81.1 million, respectively, in the prior year.
Cash and cash equivalents increased to $422.8 million as of September 30, 2026, from $319.8 million at year-end 2025, providing sufficient liquidity to fund operations and capital requirements into the second half of 2028.
Management expects to report top-line data from the REVEAL pivotal trial and receive FDA feedback on the BLA submission pathway in the first half of 2027, with a CMC Type B meeting scheduled for Q1 2027 and a follow-up CMC discussion planned for Q4 2026.
TSHA-102 manufacturing achieved successful BLA-enabling Process Performance Qualification (PPQ) with consistent quality metrics, and the asset maintains multiple FDA designations including Breakthrough Therapy and Fast Track across 33 patients with no severe treatment-related SAEs or DLTs.
Stockholders' equity rose to $357.0 million from $246.9 million at December 31, 2025, driven by capital raises, while total liabilities decreased to $78.1 million from $96.4 million, with a term loan balance of $47.3 million.